Clinical trials: Covid19 Vaccine
COVID-19 Virus Infection
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged…
- Trial name
- NCT04560881
- Testing
- Inactivated SARS-CoV-2 vaccine (Vero cell)
- Where
- 4 sites in Argentina
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
Covid19
Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults
This is a randomized, observer-blinded, Phase 1/2 study with an open-label group to evaluate the safety and immunogenicity of 3 novel SARS-CoV-2 variant vaccine constructs adjuvanted with Matrix-M1 adjuvant.
- Trial name
- NCT05029856
- Testing
- SII B.1.351, SII Bivalent, SII B.1.617.2
- Where
- 4 sites in Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novavax
Solid Tumor, Hematologic Malignancy
COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies
In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addition to more classic factors…
- Conditions
- Solid Tumor, Hematologic Malignancy, Thoracic Cancer, Cancer, Treatment-Related
- Trial name
- COVIDVAC OH (NCT04776005)
- Testing
- Data collection
- Where
- 2 sites in France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19, Oncologic Disorders
COVID-19 Vaccination in Oncologic Patients
Evaluating the vaccination willingness in oncologic patients over six months as well as estimating the effects of radiotherapy/systemic anticancer treatment on the efficacy and toxicity of currently approved SARS-CoV-2 vaccines
- Trial name
- VINCI (NCT04918888)
- Where
- 2 sites in Austria
- Volunteers
- 1,150 people
- Sponsor
- Krankenhaus Barmherzige Schwestern Linz
COVID-19, Trust
Community-Led COVID-19 Testing Intervention to Address Mistrust
The goal of this adapted intervention study is to assess how community-led group discussions about health-related topics may alter beliefs and intentions regarding healthcare recommendations, such as COVID-19 testing and…
- Trial name
- NCT07166770
- Testing
- Community-led discussion
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Old Dominion University
COVID-19
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine
Rationale: Covid-19 spreads rapidly throughout the world. A large epidemic in the Netherlands would seriously challenge the available hospital capacity, and this would be augmented by absenteeism of healthcare workers (HCW).
- Trial name
- BCG-CORONA (NCT04328441)
- Testing
- BCG Vaccine
- Where
- 9 sites in Netherlands
- Volunteers
- 1,511 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
COVID-19
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil
The present test-negative design study aims to estimate the real-world effectiveness of Pfizer-BioNTech BNT162b2 mRNA vaccine on symptomatic SARS-CoV-2 infection and its consequences among children aged 5 to 11 years in the city…
- Trial name
- NCT05403307
- Testing
- Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, CoronaVac COVID-19 vaccine
- Where
- 5 sites in Brazil
- Volunteers
- 757 people
- Sponsor
- Hospital Moinhos de Vento
Vaccine Adverse Reaction, Seroconversion
Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection
After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed.
- Trial name
- NCT04756271
- Testing
- SARS-Cov-2 neutralizing antibody titer
- Where
- Egypt
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Covid19
Biomarkers of Trained Immunity Following MMR Vaccination
This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous products, especially viral associated products…
- Trial name
- NCT04646239
- Testing
- Heterologous stimuli, Neutralization assay
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Pulmonary Fibrosis, Covid19
Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge
Methodology: This is a controlled, randomized, multicenter open-label Phase Ib clinical exploratory trial in patients with fibrosing interstitial lung disease secondary to SARS-CoV-2 infection.
- Trial name
- COVINVAC (NCT04537130)
- Testing
- IN01 vaccine
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Instituto Oncológico Dr Rosell
Cancer, Covid19
Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs.
- Trial name
- NCT04910295
- Testing
- COVID-19 vaccine
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Seoul National University Hospital
COVID-19, Vaccines
Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1
The immunogenicity and safety profiles of AdCLD-CoV19-1 (5.0×10^10 VP/dose) will be assessed for 1-dose or 2-dose regimen in SARS-CoV-2 seronegative healthy adults.
- Trial name
- NCT05520970
- Testing
- AdCLD-CoV19-1
- Where
- 4 sites in South Korea
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
COVID-19, Healthy Volunteers
Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System
Determination of both the degree and duration of the immunity provided after receiving the BNT162b2 vaccine against SARS-Cov-2.
- Conditions
- COVID-19, Healthy Volunteers, Chronic Disease, Hematological Malignancies
- Trial name
- NCT04743388
- Testing
- BNT162b2, Other vaccine against SARS-Cov-2
- Where
- Greece
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
COVID-19
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study are: To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose.
- Trial name
- VAW00001 (NCT04798027)
- Testing
- SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against…
- Trial name
- NCT05602961
- Testing
- GLB-COV2-043, BNT162b2/COMIRNATY®
- Volunteers
- healthy volunteers welcome
- Sponsor
- GreenLight Biosciences, Inc.
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or…
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT04977024
- Testing
- COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- GeoVax, Inc.
Covid19, Myopathy
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients ：a Prospective Observational Study
This study is a prospective observational study. We aim to investigate the safety and efficacy of inactivated SARS-CoV-2 vaccine between immune-related myopathy (myasthenia gravis and inflammatory myopathy) patients and health…
- Trial name
- NCT04941079
- Testing
- no intervention
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Coronavirus Disease 2019, Vaccinia
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
comparison of general characteristics of patients diagnosed COVID-19 positive followed In service
- Conditions
- Coronavirus Disease 2019, Vaccinia, Symptoms and Signs
- Trial name
- COVID-19 (NCT05092568)
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Saglik Bilimleri Universitesi
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04992208
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 31,041 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.